http://clinicaltrials.gov/ct2/show/NCT00503724 Neuro Oncology

For information on the following Clinical Trials, please contact the
Hematology, Oncology and Stem Cell Transplantation Department
at 773-880-4562 during 8:30 AM to 5:00 PM Central Standard Time.

  Newly Diagnosed Brain Tumors   Investigator 
     
  Developmental Therapeutics: Investigator
ADVL0612 A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors Stewart Goldman, MD
ADVL0813 A Phase Istudy of IMC-A12 in Combination with CCI-779 (Temsirolimus) n Pediatric Patients with Recurrent or Refractory Solid Tumors Stewart Goldman, MD
ADVL0815  A Phase I Study of Pazopanib as a Single Agent for Children with Refractory Solid Tumors Stewart Goldman, MD
ADVL0912 A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed / Refractory Solid Tumors and Anaplastic Large Cell Lymphoma Stewart Goldman, MD
ADVL0916 A Phase I Study of Vorinostat and Bortezomib in Children with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphomas.

 

 Stewart Goldman, MD
     
  High-Grade Glioma and Brain Stem Glioma   
     
  Medulloblastoma  
ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial Stewart Goldman, MD
ACNS0332 Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients Stewart Goldman, MD
ACNS0334 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate Stewart Goldman, MD
PBTC-026 A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in infants with Embryonal Tumors of the Central Nervous System Stewart Goldman, MD
     
  Germ Cell Tumors  
     
  Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors (MPNST)  
CNS 1007 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral nerve Sheath Tumors Stewart Goldman, MD
     
   Relapsed, Refractory or Progressive Brain Tumors  
ACNS0621 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Stewart Goldman, MD
CNS 1100 A Phase I Study Using Submyeloablative Dosing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors Stewart Goldman, MD
PBTC-020 A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
PBTC-027 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors Stewart Goldman, MD
TRT-014 Multi-Center, Open-Label, Expanded Access Protocol for Humanized Monoclonal Antibody (Nimotuzumab) in Patients with Recurrent Brain Stem Tumors Stewart Goldman, MD
YMB1000-013 Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive High-Grade Gliomas (including Brainstem Glioma)  
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-027 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive Low-Grade Glioma  
PBTC-022 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
PBTC-027 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive Ependymoma  
PBTC-022   
 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
PBTC-027 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive Medulloblastoma  
PBTC-022 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
PBTC-025 A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 Stewart Goldman, MD
PBTC-025B A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma Stewart Goldman, MD
PBTC-027 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors Stewart Goldman, MD
     
  Neoplastic Meningitis  
PBTC-019  A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis Stewart Goldman, MD
     
  Brain Tumor Biology Studies  

Back to the top of the page